Pharmacology: Pharmacokinetics: Flumazenil is well absorbed from the gastrointestinal tract but undergoes extensive first-pass hepatic metabolism and has a systemic bioavailability of about 20%. It is about 50% bound to plasma proteins. After intravenous administration, it is extensively metabolised in the liver to the inactive carboxylic acid form, which is excreted mainly in the urine. The elimination half-life is about 40 to 80 minutes. In patients with hepatic impairment the clearance of flumazenil is decreased with a resultant prolongation of half-life.